Division of Gastroenterology, Hepatology and Endoscopy, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Clin Gastroenterol Hepatol. 2022 Oct;20(10):2399-2401.e4. doi: 10.1016/j.cgh.2021.03.028. Epub 2021 Mar 26.
Ustekinumab has been shown to be effective for the treatment of ulcerative colitis (UC); however, >40% of patients have suboptimal clinical response after induction and maintenance dosing every 8 weeks. The best management approach for these patients is unclear. Many undergo empiric dose intensification to every 4 weeks or every 6 weeks, a nonstandardized decision because of limited data supporting therapeutic drug monitoring of ustekinumab. In Crohn's disease, approximately 50% of patients undergo ustekinumab dose intensification, which seems to be effective based on prior work from our group and others. However, similar data in UC are lacking. In this real-world multicenter cohort study, we sought to identify predictors and outcomes of ustekinumab dose intensification in UC.
乌司奴单抗已被证明对溃疡性结肠炎（UC）的治疗有效；然而，在每 8 周诱导和维持给药后，>40%的患者临床应答不佳。这些患者的最佳治疗方法尚不清楚。许多患者接受经验性剂量强化治疗，每 4 周或每 6 周一次，这是非标准化的决策，因为缺乏支持乌司奴单抗治疗药物监测的数据。在克罗恩病中，约 50%的患者接受乌司奴单抗剂量强化治疗，根据我们小组和其他小组的先前工作，这种治疗似乎是有效的。然而，UC 中缺乏类似的数据。在这项真实世界的多中心队列研究中，我们试图确定 UC 中乌司奴单抗剂量强化的预测因素和结果。
